News briefing: Regeneron/Sanofi post positive PhIII Dupixent data in pediatric asthma; Vineti scores $33M Series C extension
Regeneron and Sanofi revealed positive Phase III data for their blockbuster Dupixent on Tuesday, paving a potential path forward in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.